News

The tablet formulation of oral CR845 was formulated utilizing Enteris’ proprietary oral delivery technology under a Manufacturing and Clinical Supply Agreement. The agreement with Cara Therapeutics is representative

This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016

The drug addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which has been categorized as a serious public health threat by the US Centers

The Carbapenem Resistance Consortium aims to develop a rapid diagnostic test, which can target multi-drug resistant pathogens and support the appropriate use of antibiotics. Xpert Carba-R, which is

MGD006 is a humanized, Dual-Affinity Re-Targeting (DART(R)) bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. The study,

The double-blind and placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of single oral doses of Debio 1450 in healthy subjects. Debio 1450 is an anti-infective agent

In partnership with Sanofi, Merrimack completed an extensive Phase II program for MM-121 which was designed to assess the role of ErbB3 in a number of cancer indications

Kala has initiated dosing in its Phase III trial (KPI-121-C-001) to evaluate the safety and efficacy of LE-MPP in managing inflammation and pain associated with cataract surgery. In

Proceeds from the financing will be used to augment Navitor’s proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs that target cellular nutrient